Literature DB >> 21427128

Defective survival of proliferating Sertoli cells and androgen receptor function in a mouse model of the ATR-X syndrome.

Stefan Bagheri-Fam1, Anthony Argentaro, Terje Svingen, Alexander N Combes, Andrew H Sinclair, Peter Koopman, Vincent R Harley.   

Abstract

X-linked ATR-X (alpha thalassemia, mental retardation, X-linked) syndrome in males is characterized by mental retardation, facial dysmorphism, alpha thalassemia and urogenital abnormalities, including small testes. It is unclear how mutations in the chromatin-remodeling protein ATRX cause these highly specific clinical features, since ATRX is widely expressed during organ development. To investigate the mechanisms underlying the testicular defects observed in ATR-X syndrome, we generated ScAtrxKO (Sertoli cell Atrx knockout) mice with Atrx specifically inactivated in the supporting cell lineage (Sertoli cells) of the mouse testis. ScAtrxKO mice developed small testes and discontinuous tubules, due to prolonged G2/M phase and apoptosis of proliferating Sertoli cells during fetal life. Apoptosis might be a consequence of the cell cycle defect. We also found that the onset of spermatogenesis was delayed in postnatal mice, with a range of spermatogenesis defects evident in adult ScAtrxKO mice. ATRX and the androgen receptor (AR) physically interact in the testis and in the Sertoli cell line TM4 and co-operatively activate the promoter of Rhox5, an important direct AR target. We also demonstrate that ATRX directly binds to the Rhox5 promoter in TM4 cells. Finally, gene expression of Rhox5 and of another AR-dependent gene, Spinlw1, was reduced in ScAtrxKO testes. These data suggest that ATRX can directly enhance the expression of androgen-dependent genes through physical interaction with AR. Recruitment of ATRX by DNA sequence-specific transcription factors could be a general mechanism by which ATRX achieves tissue-specific transcriptional regulation which could explain the highly specific clinical features of ATR-X syndrome when ATRX is mutated.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21427128     DOI: 10.1093/hmg/ddr109

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  27 in total

Review 1.  Mutant ATRX: uncovering a new therapeutic target for glioma.

Authors:  Santiago Haase; María Belén Garcia-Fabiani; Stephen Carney; David Altshuler; Felipe J Núñez; Flor M Méndez; Fernando Núñez; Pedro R Lowenstein; Maria G Castro
Journal:  Expert Opin Ther Targets       Date:  2018-06-20       Impact factor: 6.902

2.  PML is recruited to heterochromatin during S phase and represses DAXX-mediated histone H3.3 chromatin assembly.

Authors:  Prashanth Krishna Shastrula; Isabel Sierra; Zhong Deng; Frederick Keeney; James E Hayden; Paul M Lieberman; Susan M Janicki
Journal:  J Cell Sci       Date:  2019-03-26       Impact factor: 5.285

3.  Ghrelin partially protects against cisplatin-induced male murine gonadal toxicity in a GHSR-1a-dependent manner.

Authors:  Shannon D Whirledge; Jose M Garcia; Roy G Smith; Dolores J Lamb
Journal:  Biol Reprod       Date:  2015-01-28       Impact factor: 4.285

Review 4.  Role of ATRX in chromatin structure and function: implications for chromosome instability and human disease.

Authors:  Rabindranath De La Fuente; Claudia Baumann; Maria M Viveiros
Journal:  Reproduction       Date:  2011-06-08       Impact factor: 3.906

Review 5.  Disorders of sex development: new genes, new concepts.

Authors:  Makoto Ono; Vincent R Harley
Journal:  Nat Rev Endocrinol       Date:  2012-12-18       Impact factor: 43.330

6.  Daxx Functions Are p53-Independent In Vivo.

Authors:  Amanda R Wasylishen; Jeannelyn S Estrella; Vinod Pant; Gilda P Chau; Guillermina Lozano
Journal:  Mol Cancer Res       Date:  2018-06-14       Impact factor: 5.852

7.  Atrx deficiency induces telomere dysfunction, endocrine defects, and reduced life span.

Authors:  L Ashley Watson; Lauren A Solomon; Jennifer Ruizhe Li; Yan Jiang; Matthew Edwards; Kazuo Shin-ya; Frank Beier; Nathalie G Bérubé
Journal:  J Clin Invest       Date:  2013-04-08       Impact factor: 14.808

8.  Compromised genomic integrity impedes muscle growth after Atrx inactivation.

Authors:  Michael S Huh; Tina Price O'Dea; Dahmane Ouazia; Bruce C McKay; Gianni Parise; Robin J Parks; Michael A Rudnicki; David J Picketts
Journal:  J Clin Invest       Date:  2012-11-01       Impact factor: 14.808

9.  An essential role for insulin and IGF1 receptors in regulating sertoli cell proliferation, testis size, and FSH action in mice.

Authors:  Jean-Luc Pitetti; Pierre Calvel; Céline Zimmermann; Béatrice Conne; Marilena D Papaioannou; Florence Aubry; Christopher R Cederroth; Françoise Urner; Betty Fumel; Michel Crausaz; Mylène Docquier; Pedro Luis Herrera; François Pralong; Marc Germond; Florian Guillou; Bernard Jégou; Serge Nef
Journal:  Mol Endocrinol       Date:  2013-03-21

10.  Loss of Atrx sensitizes cells to DNA damaging agents through p53-mediated death pathways.

Authors:  Damiano Conte; Michael Huh; Emma Goodall; Marilyne Delorme; Robin J Parks; David J Picketts
Journal:  PLoS One       Date:  2012-12-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.